Something has changed in aesthetic medicine over the past several years — and it goes beyond trends. After more than a decade in which the dominant approach involved adding volume with hyaluronic acid fillers and relaxing muscles with injectable toxin, we are seeing a meaningful shift in how both practitioners and patients think about what good aesthetic treatment should achieve.
The question being asked increasingly in consultation rooms — and in the clinical literature — is not "how do we add?" but "how do we restore?" That distinction is the foundation of what is now broadly referred to as regenerative aesthetic medicine: an approach that prioritises the stimulation of the body's own biological processes over the direct injection of external material. Biostimulators sit at the heart of this movement, and Sculptra, the original and most extensively studied biostimulator, is more clinically relevant today than at any point since its approval.
What are biostimulators?
Biostimulators are a category of injectable treatment that work not by directly replacing lost tissue, but by triggering the body's own regenerative response — stimulating fibroblasts (the cells responsible for producing collagen, elastin, and hyaluronic acid) to produce new structural proteins. The results are gradual, progressive, and — critically — the patient's own biology is doing the work.
The category includes several distinct products and mechanisms:
- Poly-L-lactic acid (PLLA) — Sculptra. The original and most clinically evidenced biostimulator. Microparticles suspended in water trigger a controlled inflammatory response that stimulates fibroblast activity and new collagen formation.
- Calcium hydroxylapatite (CaHA) — Radiesse. A synthetic mineral compound that provides immediate structural support while simultaneously stimulating collagen and elastin production.
- Polynucleotides (PDRN) — including Pilnest and NEWEST. Purified DNA fragments that activate cellular repair pathways, improving skin quality, barrier function, and hydration at a cellular level.
- High-concentration hyaluronic acid bioremodellers — Profhilo and similar products. While not strictly collagen-stimulating in the same mechanism, these work by inducing a biological remodelling response that stimulates collagen and elastin synthesis as well as providing deep hydration.
What unites them is the principle of working with the body rather than simply augmenting it — and it is this principle that increasingly defines the direction in which evidence-based aesthetic medicine is travelling.
"The best aesthetic outcome is one the patient's own biology has largely produced. Our role is to create the conditions in which that can happen."
Sculptra: mechanism and indications
Sculptra (poly-L-lactic acid) is a synthetic, biocompatible, biodegradable polymer — the same material used in dissolvable sutures — formulated as sterile microparticles suspended in water. When injected into the deep dermis or subcutaneous tissue, it stimulates a localised, controlled inflammatory response. Fibroblasts are recruited to the area, where they produce new Type I and Type III collagen — the primary structural proteins of the skin. As the PLLA particles are gradually reabsorbed over several months, the collagen they have stimulated remains, providing progressive, natural volume restoration and improved skin quality.
The results of Sculptra are characteristically different from those of hyaluronic acid fillers. There is no immediate volumising effect — which can feel counterintuitive at first. Instead, results develop gradually over three to six months following a treatment course, typically consisting of two to three sessions spaced six to eight weeks apart. The benefit of this delayed mechanism is that the outcome integrates naturally with the patient's existing anatomy, producing results that are genuinely difficult to identify as aesthetic treatment. Volume is restored rather than added; structure is rebuilt rather than supported.
Sculptra is indicated for a broad range of presentations:
- Age-related facial volume loss and soft tissue atrophy
- Improvement of skin laxity and quality across the face and body
- Temple hollowing and midface deflation
- Jawline and chin structural loss
- Décolletage and neck skin quality
- Body applications including buttock augmentation, knee and arm laxity
- Rapid volume loss from any cause — including illness, significant weight loss, and medication-related lipoatrophy
Results from Sculptra can last two years or more, making it one of the most cost-effective aesthetic treatments available when considered over time — and one of the least interventionist in terms of frequency of treatment required.
Where Sculptra began: HIV-associated lipoatrophy
To understand Sculptra's clinical pedigree, it is worth returning to its origins — because they are not cosmetic. Sculptra was first approved in 1999 in Europe (under the name New-Fill) and in 2004 by the FDA in the United States specifically for the treatment of HIV-associated facial lipoatrophy: the severe, often deeply distressing loss of facial fat that affected many people living with HIV as a side effect of the antiretroviral therapies used at the time, particularly the older nucleoside reverse transcriptase inhibitors (NRTIs).
The condition caused dramatic hollowing of the cheeks, temples, and periorbital areas, along with pronounced skin laxity — changes that were both physically disfiguring and psychologically significant, often visibly marking patients as HIV-positive at a time when that carried serious social stigma. Sculptra restored lost facial structure progressively and naturally, without the risks associated with implants or the maintenance burden of regular filler treatments. The clinical evidence from this patient population established the safety and efficacy profile that underpinned its later cosmetic approval in 2009.
This history matters because it demonstrates that Sculptra's most powerful clinical application is not cosmetic refinement — it is the restoration of facial structure in patients who have experienced significant, rapid tissue loss from a systemic cause. That original indication turns out to be extraordinarily relevant to a new and rapidly growing patient population.
GLP-1 medications and the new lipoatrophy
The dramatic rise in the use of GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — has created a new and widespread clinical challenge in aesthetic medicine. These medications are highly effective for weight management and type 2 diabetes, and their use is growing rapidly. But significant, often rapid weight loss — particularly when it occurs over a compressed timeframe — has consequences for facial appearance that patients and prescribers are increasingly seeking to address.
Rapid weight loss depletes facial fat compartments — the structural pads of fat that give the face its three-dimensional architecture and youthful proportion. The temples hollow. The midface deflates. The cheeks lose their support. Nasolabial folds deepen sharply. The jawline softens and jowls become more prominent. The skin, having lost the subcutaneous support that kept it taut, begins to sag. The overall effect — colloquially known as "Ozempic face" — can add years to the appearance in a matter of months, and is often profoundly distressing to patients who have worked hard to achieve their weight loss goals.
The parallel with HIV lipoatrophy is not merely metaphorical. Both conditions involve rapid, systemic depletion of facial fat with consequent structural collapse and skin laxity. Both affect patients who are otherwise well and whose weight management is clinically appropriate. And both respond — as the evidence increasingly shows — to the same biostimulating approach that Sculptra was originally developed to address.
"The clinical challenge of GLP-1 facial volume loss maps almost exactly onto the original indication that brought Sculptra into existence. The solution is the same; only the cause has changed."
The evidence: starting early matters
One of the most important clinical insights emerging from the growing literature on GLP-1-related facial changes is the value of early intervention. Waiting until volume loss is severe before treating creates a significantly more complex and less satisfying clinical picture — one in which the skin has already begun to adapt to its depleted support structure, laxity has set in, and restoration requires more product, more sessions, and produces less natural outcomes.
The emerging consensus among leading practitioners is that patients on GLP-1 medications should be assessed for facial changes early — ideally at the point of commencing treatment — and that preventive or early restorative biostimulator therapy, combined where appropriate with hyaluronic acid support, produces substantially better outcomes than reactive treatment of established volume loss.
This principle is supported by a significant piece of clinical evidence: a multicentre, open-label study by Lorenc et al. examining a combined poly-L-lactic acid and hyaluronic acid mid-face filler regimen in patients using GLP-1 medications. The study demonstrated that this combined approach — biostimulator to rebuild collagen and structural integrity, with targeted hyaluronic acid to address immediate volume deficit — meaningfully enhanced facial harmony and skin quality in this patient group. The findings reinforce the clinical rationale for treating GLP-1-related facial changes with the same regenerative framework applied to HIV lipoatrophy: structural restoration through collagen stimulation, complemented by targeted volume replacement where needed.
The Lorenc et al. study is particularly valuable because it addresses not only efficacy but also the sequencing of treatment — providing a framework for practitioners managing this rapidly growing patient cohort. It supports a model in which Sculptra is used to rebuild the collagen architecture that rapid weight loss has depleted, with hyaluronic acid fillers used selectively and sparingly to address specific areas of volume deficit rather than as the primary intervention.
The broader shift: regenerative aesthetic medicine
The clinical evolution described above reflects something larger happening across aesthetic medicine. The field is moving — supported by an expanding evidence base and by shifting patient expectations — away from the heavily augmented aesthetic that dominated much of the 2010s and toward an approach that prioritises restoration, quality, and longevity over immediate visible change.
Patients are asking different questions in consultation. They are less likely to request specific products or volumes, and more likely to ask how they can look like themselves again — rested, well, naturally proportionate. They are more suspicious of results that look "done" and more interested in treatments that work gradually and integrate seamlessly. They are also, in many cases, dealing with the consequences of earlier treatment decisions and seeking practitioners who will address the underlying tissue changes rather than compound them with additional filler.
Regenerative aesthetic medicine answers these questions with a coherent clinical philosophy. Rather than compensating for the loss of collagen and volume by importing material from outside, it works to restore the skin's intrinsic capacity to support itself — through biostimulators that recruit the body's own fibroblasts, through polynucleotide treatments that repair cellular function, through skin boosters that replenish hyaluronic acid at the level of the dermis. The aesthetic result is natural because the biology producing it is the patient's own.
Sculptra, with its twenty-five-year clinical history and its roots in the treatment of medically significant tissue loss, is not a product of this trend — it is its foundation. It represents what good aesthetic medicine has always been capable of when it works in partnership with the body rather than in spite of it.
Is Sculptra right for you?
Sculptra is suitable for a wide range of presentations — from early, subtle volume loss in a patient in their late 30s to more significant structural depletion in someone in their 50s or 60s, or in anyone who has experienced rapid weight loss for any reason. It works best when the expectation is set clearly: the results are gradual, progressive, and designed to look completely natural. They do not produce the immediate transformation that some aesthetic treatments offer — and that is precisely the point.
For patients currently using or considering GLP-1 medications, I would strongly encourage a consultation before or early in the course of treatment. The evidence is clear that managing facial changes proactively — rather than reactively — produces significantly better outcomes. A conversation about what to expect, and how to protect the face's structural integrity as weight changes, costs nothing and can make a meaningful difference to both the clinical result and the patient's experience of their treatment journey.
Reference: Lorenc ZP et al. A multicentre, open-label study of a combined poly-L-lactic acid and hyaluronic acid mid-face filler regimen enhances facial harmony and skin quality in GLP-1 medication users.
Book a Complimentary Consultation
Whether you are considering Sculptra, navigating changes from GLP-1 medications, or simply want to understand what a regenerative approach could offer you — I would love to talk it through.
Get in touch